Pfizer Ends Global Partnership with Sangamo, Shares Plummet 27%

Sangamo's shares fell by approximately 27% in response to Pfizer's decision to terminate the global collaboration and licensing agreement between the two companies. The termination of the agreement will take effect on April 21, 2025. Following this decision, Sangamo began exploring other options and potential partners to continue advancing its program. Pfizer's decision to end the partnership primarily stems from its choice to not proceed with the Biologics License Application and Marketing Authorization Application submissions for giroctocogene fitelparvovec. The pharmaceutical giant also does not have plans to continue the commercialization of this particular biological product.